Healthcare DIVE November 13, 2024
Rebecca Pifer

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.

Dive Brief:

  • Johnson & Johnson is suing the Biden administration for blocking a controversial change to how the pharmaceutical company divvies out drug discounts to hospitals in a federal savings program.
  • This summer, J&J unveiled a plan to give hospitals after-the-fact rebates for two medications in the program, called 340B, instead of upfront discounts, but paused implementation following threats of government sanctions. The lawsuit filed Tuesday in a district court seeks a ruling finding J&J’s plan legal and allowing the drugmaker to roll out the model.
  • It’s the latest salvo...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Pharma, Pharma / Biotech, Provider
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease

Share This Article